Galectin Therapeutics 的药物在减少静脉曲张方面显示出希望，但在肝硬化试验中未达到主要目标。 Galectin Therapeutics' drug shows promise in reducing varices but misses primary goal in cirrhosis trial.

Galectin Therapeutics 在肝硬化门静脉高压症患者中针对贝拉帕菌素的 NAVIGATE 试验显示，在符合方案的人群中，新静脉曲张显着减少了 48.9%，但未能达到总人群的主要终点。 Galectin Therapeutics' NAVIGATE trial for belapectin in patients with cirrhotic portal hypertension showed a significant 48.9% reduction in new varices in the per-protocol population but failed to meet the primary endpoint for the overall population. 该药物的开销良好,不良事件没有增加。 The drug was well-tolerated with no increase in adverse events. 该公司计划于2025年初提供进一步更新和生物标志数据。 The company plans to provide further updates and biomarker data in early 2025.